Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)
Hong Kong · Delayed Price · Currency is HKD 1.180
0.00 (0.00%)
At close: Feb 13, 2026
HKG:2348 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,113 | 1,060 | 1,151 | 1,278 | 1,165 | 1,024 | |
Revenue Growth (YoY) | 3.21% | -7.89% | -9.90% | 9.66% | 13.76% | 7.82% |
Cost of Revenue | 603.83 | 528.25 | 522.67 | 511 | 489.79 | 478.72 |
Gross Profit | 509.46 | 532.06 | 628.48 | 766.68 | 675.36 | 545.55 |
Selling, General & Admin | 259.47 | 258.2 | 260.26 | 264.79 | 226.44 | 163.8 |
Research & Development | 83.76 | 70.83 | 90.81 | 79.48 | 67.03 | 57.94 |
Other Operating Expenses | 0.62 | 0.97 | 1.43 | 3.31 | 1.13 | 3.32 |
Operating Expenses | 343.84 | 330.01 | 352.49 | 347.58 | 294.6 | 225.06 |
Operating Income | 165.62 | 202.05 | 275.99 | 419.1 | 380.76 | 320.5 |
Interest Expense | -1.26 | -3.61 | -0.99 | -0.37 | -0.64 | -4.83 |
Interest & Investment Income | 38.72 | 37.04 | 26.55 | 19.85 | 20.23 | 17.46 |
Earnings From Equity Investments | - | -3.7 | -40.93 | -61.91 | -46.42 | -18.77 |
Currency Exchange Gain (Loss) | -1.76 | -5.55 | -5.53 | -4.54 | 1 | -1.48 |
Other Non Operating Income (Expenses) | 14.76 | 122.03 | 153.54 | 20.21 | 9.72 | 20.97 |
EBT Excluding Unusual Items | 216.07 | 348.27 | 408.64 | 392.36 | 364.65 | 333.85 |
Gain (Loss) on Sale of Investments | 6.6 | 292.89 | 5.68 | 7.2 | 5.56 | - |
Gain (Loss) on Sale of Assets | -4.54 | -4.21 | -0.26 | 38.84 | 69.11 | -0.46 |
Asset Writedown | -7.62 | - | - | - | - | -2.09 |
Other Unusual Items | - | - | - | 0.01 | - | - |
Pretax Income | 210.51 | 636.95 | 414.06 | 438.41 | 439.32 | 331.3 |
Income Tax Expense | 37.63 | 74.19 | 91.39 | 82.56 | 85.16 | 66.51 |
Earnings From Continuing Operations | 172.89 | 562.76 | 322.67 | 355.85 | 354.16 | 264.79 |
Minority Interest in Earnings | 3.58 | 2.18 | 3.33 | 2.21 | 4.01 | 3.34 |
Net Income | 176.47 | 564.94 | 326 | 358.06 | 358.18 | 268.13 |
Net Income to Common | 176.47 | 564.94 | 326 | 358.06 | 358.18 | 268.13 |
Net Income Growth | -68.66% | 73.29% | -8.95% | -0.03% | 33.58% | 4.97% |
Shares Outstanding (Basic) | 1,506 | 1,505 | 1,500 | 1,499 | 1,498 | 1,545 |
Shares Outstanding (Diluted) | 1,506 | 1,506 | 1,503 | 1,502 | 1,508 | 1,546 |
Shares Change (YoY) | 0.28% | 0.22% | 0.02% | -0.37% | -2.44% | -1.89% |
EPS (Basic) | 0.12 | 0.38 | 0.22 | 0.24 | 0.24 | 0.17 |
EPS (Diluted) | 0.12 | 0.38 | 0.22 | 0.24 | 0.24 | 0.17 |
EPS Growth | -68.75% | 72.90% | -8.94% | 0.34% | 36.89% | 7.03% |
Free Cash Flow | 195.9 | 94.16 | 138.85 | 229.9 | 80.07 | 163.8 |
Free Cash Flow Per Share | 0.13 | 0.06 | 0.09 | 0.15 | 0.05 | 0.11 |
Dividend Per Share | 0.059 | 0.059 | 0.073 | 0.078 | 0.065 | 0.055 |
Dividend Growth | -18.93% | -18.48% | -6.71% | 19.44% | 19.08% | 5.56% |
Gross Margin | 45.76% | 50.18% | 54.60% | 60.00% | 57.96% | 53.26% |
Operating Margin | 14.88% | 19.06% | 23.97% | 32.80% | 32.68% | 31.29% |
Profit Margin | 15.85% | 53.28% | 28.32% | 28.02% | 30.74% | 26.18% |
Free Cash Flow Margin | 17.60% | 8.88% | 12.06% | 17.99% | 6.87% | 15.99% |
EBITDA | 248.37 | 302.83 | 354.43 | 480.06 | 433.89 | 373.09 |
EBITDA Margin | 22.31% | 28.56% | 30.79% | 37.57% | 37.24% | 36.43% |
D&A For EBITDA | 82.76 | 100.78 | 78.44 | 60.96 | 53.13 | 52.6 |
EBIT | 165.62 | 202.05 | 275.99 | 419.1 | 380.76 | 320.5 |
EBIT Margin | 14.88% | 19.06% | 23.97% | 32.80% | 32.68% | 31.29% |
Effective Tax Rate | 17.87% | 11.65% | 22.07% | 18.83% | 19.38% | 20.07% |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.